S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Closing prices for crude oil, gold and other commodities
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:DNLI

Denali Therapeutics (DNLI) Stock Price, News & Analysis

$16.82
-0.52 (-3.00%)
(As of 04/17/2024 ET)
Today's Range
$16.79
$17.56
50-Day Range
$16.53
$23.35
52-Week Range
$15.45
$33.31
Volume
1.37 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.22

Denali Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
145.1% Upside
$41.22 Price Target
Short Interest
Bearish
8.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.27mentions of Denali Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.22 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.62) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

263rd out of 913 stocks

Biological Products, Except Diagnostic Industry

33rd out of 134 stocks

DNLI stock logo

About Denali Therapeutics Stock (NASDAQ:DNLI)

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI Stock Price History

DNLI Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
DNLI Apr 2024 12.500 put
DNLI Apr 2024 10.000 call
DNLI Apr 2024 17.500 put
4 Analysts Assess Denali Therapeutics: What You Need To Know
Denali spikes after $500M private placement
See More Headlines
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/17/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:DNLI
Fax
N/A
Employees
445
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$41.22
High Stock Price Target
$95.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+145.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-145,220,000.00
Pretax Margin
-43.93%

Debt

Sales & Book Value

Annual Sales
$330.53 million
Book Value
$7.42 per share

Miscellaneous

Free Float
128,166,000
Market Cap
$2.34 billion
Optionable
Optionable
Beta
1.33

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Ryan J. Watts Ph.D. (Age 48)
    Co-Founder, President, CEO & Director
    Comp: $1.04M
  • Dr. Alexander O. Schuth M.D.Dr. Alexander O. Schuth M.D. (Age 51)
    Co-Founder, CFO, COO & Secretary
    Comp: $737.2k
  • Dr. Marc Tessier-Lavigne Ph.D. (Age 64)
    Co-Founder & Independent Director
    Comp: $58.23k
  • Dr. Carole Ho M.D. (Age 51)
    Chief Medical Officer & Head of Development
    Comp: $737.2k
  • Mr. Tyler M. Nielsen (Age 46)
    Senior Vice President of Corporate Finance
  • Dr. Dana Andersen
    Chief Technical and Manufacturing Officer
  • Mr. Joe Lewcock Ph.D.
    Chief Scientific Officer
  • Dr. Laura Hansen
    Vice President of Investor Relations
  • Mr. Chris Walsh
    General Counsel
  • Mr. Mark Rowen
    Vice President of Corporate Development

DNLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Denali Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings
or view top-rated stocks.

What is Denali Therapeutics' stock price target for 2024?

8 brokers have issued twelve-month price targets for Denali Therapeutics' stock. Their DNLI share price targets range from $28.00 to $95.00. On average, they predict the company's share price to reach $41.22 in the next year. This suggests a possible upside of 145.1% from the stock's current price.
View analysts price targets for DNLI
or view top-rated stocks among Wall Street analysts.

How have DNLI shares performed in 2024?

Denali Therapeutics' stock was trading at $21.46 at the start of the year. Since then, DNLI shares have decreased by 21.6% and is now trading at $16.82.
View the best growth stocks for 2024 here
.

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 12.3% from the March 15th total of 8,380,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is currently 8.0 days. Currently, 8.4% of the shares of the company are short sold.
View Denali Therapeutics' Short Interest
.

When is Denali Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DNLI earnings forecast
.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its earnings results on Tuesday, February, 27th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05. Denali Therapeutics had a negative trailing twelve-month return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter last year, the business posted ($0.75) EPS.

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Denali Therapeutics own?
When did Denali Therapeutics IPO?

Denali Therapeutics (DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Denali Therapeutics?

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DNLI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners